The most consequential M&A story in the vape market is Altria's $2.75 billion acquisition of NJOY (completed June 2023), which has gone spectacularly wrong:
| Event | Date | Impact |
|---|---|---|
| Altria acquires NJOY | Jun 2023 | $2.75B deal, entry into e-cig market |
| Altria's JUUL stake written to zero | 2023-2024 | $12.8B investment (35% stake) fully impaired |
| ITC ruling: NJOY ACE infringes JUUL patents | Mar 2025 | Import ban through 2034/2037; ACE sales halted |
| Altria total e-cig share: 11.4% → 8.2% | Q2 2025 → Q2 2026 | -3.2pp — fastest share loss in market |
| JUUL patent win confirmed | Aug 2026 | Forces NJOY product line restructuring |
"Altria's NJOY acquisition has become a case study in how not to enter a regulated market. They paid $2.75 billion for a company whose flagship product was banned from import 18 months later."
Meanwhile, JUUL — which Altria had abandoned — is being redeployed into 6,000 Walgreens locations and is gaining retail distribution through Sycamore Partners' pharmacy network. The irony is sharp: Altria's failed NJOY bet may have indirectly strengthened JUUL, the company Altria once owned 35% of and wrote down to zero.
No other major M&A has occurred in 2025-2026. The market remains fragmented among Chinese manufacturers (Elf Bar, Geek Bar, Lost Mary) and Big Tobacco legacy brands (JUUL, Vuse, NJOY). Industry consolidation is more likely to happen through regulatory attrition — small players exiting as FDA enforcement makes PMTA compliance costs prohibitive — than through acquisitions. For a deeper look at how JUUL's patent strategy reshaped the competitive landscape, see our JUUL2 FDA authorization analysis.
